Skip to main content
OpenTrials
Completed

NCT Number: NCT05066360

Serum Antimullerian Hormone Levels Among Epileptic Patients

The production of AMH starts in granulosa cells before birth and the levels within the serum decreases towards the menapouse. The levels of AMH do not change throughout the menstruation cycle hovewer, it can be affected in cases related to body mass index (BMI), polycyctic ovarian syndrome (PCOS). The lower levels of AMH had been documented after ovarian surgery, radiotheraphy and chemotheraphy. AMH is a member of Transforming Growth Faktor β (TGF- β ) and it has receptors in brain structures including hyppocammpus. It is highly active neurophysiologically and it has a protective effect against N-methyl-D -aspartate related neuronal injury that is demonstrated both in vivo and in vitro studies. As a result, being a neuroactive hormone; AMH may have an effect on seizures within epileptic patients or serum AMH levels may be effected in epileptic patients when compared with healthy ones.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–18 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Near East University Faculty of Medicine

Nicosia, 99138, Cyprus

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy and epileptic volunteer females
  • Ages between 12-18
  • After menarche

Exclusion criteria

  • ovarian surgery,
  • history of radiotherapy
  • history of chemotherapy,
  • before menarche

Treatment and study plan

serum antimullerian hormone

Diagnostic Test

serum antimullerian hormone will be analyzed for all participants

Primary outcomes

  1. serum anti-mullerian hormone levels

    Time frame: baseline, at the time of examination

    The comparison of serum levels of anti-mullerian hormone between epileptic and healthy groups

Sponsors and collaborators

Lead sponsor

Near East University, Turkey

Other

Registry information

Official study title

Investigation of Serum Antimullerian Hormone Levels in Adolescent Epilepsy Patients

Important dates

Study start
2021
Primary completion
2022
Study completion
2023
First posted
Oct 4, 2021
Registry last updated
Jan 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.